4.8 Article

Prognostic value of complement serum C3 level and glomerular C3 deposits in anti-glomerular basement membrane disease

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Urology & Nephrology

Risk Stratification to Predict Renal Survival in Anti-Glomerular Basement Membrane Disease

Lauren Floyd et al.

Summary: This study investigated clinical and histologic parameters in patients with anti-glomerular basement membrane (anti-GBM) disease to predict kidney outcomes and identify patients who may benefit from rescue immunosuppressive therapy. Stratifying patients based on the need for renal replacement therapy at diagnosis and renal histology improved prediction accuracy, emphasizing the importance of normal glomeruli.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Article Transplantation

The role of complement in glomerulonephritis-are novel therapies ready for prime time?

Chee Kay Cheung et al.

Summary: This article discusses the potential benefits and challenges of targeting the complement system in glomerular disease, and summarizes the current understanding of complement's role and the novel targeted therapies being developed for the treatment of glomerular disease.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Urology & Nephrology

Predictors of Kidney Outcomes of Anti-Glomerular Basement Membrane Disease in a Large Chinese Cohort

Xiao-Yan Jia et al.

Summary: Anti-glomerular basement membrane (GBM) disease is a rare but aggressive form of glomerulonephritis, and the prognosis of patients has improved over the past few decades. Serum creatinine and crescent percentage at diagnosis are predictors for kidney outcomes, while positive antineutrophil cytoplasmic antibodies (ANCAs) are predictors for mortality.

AMERICAN JOURNAL OF NEPHROLOGY (2022)

Review Urology & Nephrology

The Rational Use of Complement Inhibitors in Kidney Diseases

Fadi Fakhouri et al.

Summary: The development of complement inhibitors has brought about significant advancements in the field of clinical nephrology, particularly in the treatment of severe kidney diseases such as atypical hemolytic uremic syndrome. The availability of these inhibitors has also opened up new possibilities for managing other kidney diseases where complement activation is involved. However, the rational usage of these costly therapeutic agents is crucial, especially with the increasing number of inhibitors being tested for various indications. This review aims to summarize the current knowledge and gaps regarding complement activation and therapeutic inhibition in kidney diseases, while providing insights for a rational approach to complement modulation.

KIDNEY INTERNATIONAL REPORTS (2022)

Review Urology & Nephrology

Epidemiology, Impact, and Management Strategies of Anti-Glomerular Basement Membrane Disease

Muhammad Asim et al.

Summary: Anti-glomerular basement membrane (anti-GBM) disease is a rare autoimmune disease that can cause kidney and lung hemorrhage. Environmental factors may trigger the disease. Early diagnosis and combined therapy can improve patient prognosis.

INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE (2022)

Article Immunology

Relationship Between Serum Complement C3 Levels and Outcomes Among Patients With Anti-GBM Disease

Mengyue Zhu et al.

Summary: This study investigated the relationship between serum C3 levels and outcomes in patients with anti-GBM disease, and found that patients in the low C3 group had poorer kidney outcomes.

FRONTIERS IN IMMUNOLOGY (2022)

Article Medicine, General & Internal

Anti-glomerular Basement Membrane Glomerulonephritis: A Study in Real Life

Marina Sanchez-Agesta et al.

Summary: In this study, the clinical and pathological features predicting the progression of end-stage kidney disease (ESKD) and kidney survival in patients with anti-glomerular basement membrane (anti-GBM) disease were evaluated. The results showed that patients with severe disease, defined as creatinine levels > 4.7 mg/dL and > 50% crescents, had poor renal prognosis despite plasma exchange and immunosuppressive treatment. New therapies are urgently needed for the treatment of this rare renal disease.

FRONTIERS IN MEDICINE (2022)

Article Medicine, General & Internal

Avacopan for the Treatment of ANCA-Associated Vasculitis

David R. W. Jayne et al.

Summary: In this study, the C5a receptor inhibitor avacopan was found to be noninferior to prednisone taper in achieving remission at week 26, but superior in achieving sustained remission at week 52 in patients with ANCA-associated vasculitis. All patients received cyclophosphamide or rituximab. The safety and clinical effects of avacopan beyond 52 weeks were not addressed in the trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Review Rheumatology

A Review of Complement Activation in SLE

Arthur Weinstein et al.

Summary: Abnormal levels of plasma complement split products and cell-bound complement activation products support complement activation as an important pathogenetic mechanism in SLE and show promise for the diagnosis and monitoring of disease activity.

CURRENT RHEUMATOLOGY REPORTS (2021)

Article Immunology

Disease activity prediction and prognosis of anti-GBM nephritis based on T lymphocyte subset ratios

Dan Zhang et al.

Summary: The CD4+/CD8+ ratio is associated with disease activity, renal fibrosis, and prognosis of anti-GBM disease, with a high ratio indicating a poor renal outcome.

INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2021)

Article Allergy

The Immunopathology of Complement Proteins and Innate Immunity in Autoimmune Disease

Federica Defendi et al.

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2020)

Article Biochemistry & Molecular Biology

Complement-mediated kidney diseases

Felix Poppelaars et al.

MOLECULAR IMMUNOLOGY (2020)

Review Immunology

New insights into the immune functions of complement

Edimara S. Reis et al.

NATURE REVIEWS IMMUNOLOGY (2019)

Article Urology & Nephrology

Development and validation of a renal risk score in ANCA-associated glomerulonephritis

Silke R. Brix et al.

KIDNEY INTERNATIONAL (2018)

Review Critical Care Medicine

Antiglomerular Basement Membrane Disease

Stephen P. McAdoo et al.

SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2018)

Article Urology & Nephrology

Predicting Outcome in Patients with Anti-GBM Glomerulonephritis

Emma E. van Daalen et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)

Article Urology & Nephrology

Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis

David R. W. Jayne et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)

Review Urology & Nephrology

Complement in ANCA-associated vasculitis: mechanisms and implications for management

Min Chen et al.

NATURE REVIEWS NEPHROLOGY (2017)

Review Medical Laboratory Technology

Complement in autoimmune diseases

Pandiarajan Vignesh et al.

CLINICA CHIMICA ACTA (2017)

Article Transplantation

Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort

Bassam Alchi et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)

Article Rheumatology

2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

J. C. Jennette et al.

ARTHRITIS AND RHEUMATISM (2013)

Review Critical Care Medicine

Alveolar Hemorrhage in Vasculitis: Primary and Secondary

Jean-Francois Cordier et al.

SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2011)

Article Immunology

Analysis of T cell responses to the autoantigen in Goodpasture's disease

C. J. DERRY et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)

Article Urology & Nephrology

Histopathologic Classification of ANCA-Associated Glomerulonephritis

Annelies E. Berden et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)

Review Immunology

T-cell regulation: with complements from innate immunity

Claudia Kemper et al.

NATURE REVIEWS IMMUNOLOGY (2007)